Disability

Real World Data Supports Results of Route 92 Medical’s SUMMIT MAX Clinical Trial

Company also announces new 500-patient SUMMIT RISE study at the Society of NeuroInterventional Surgery annual meetingSAN MATEO, Calif., July 14,…

6 months ago

Qanatpharma, Zuse Institute Berlin, Enamine, and Proteros biostructures Announce Generative-AI Driven Lead Discovery Collaboration

Joint research program targets new treatments for life-threatening complication of brain hemorrhage An international discovery collaboration is harnessing AI-powered drug…

6 months ago

Morgan AH Medical Unveils Patented Rolling Expandable Bathtub at Abilities Expo Chicago – Hailed as a “Game Changer” for Accessible Bathing

Chicago, Illinois--(Newsfile Corp. - July 3, 2025) - Morgan AH Medical made headlines at this year's Abilities Expo Chicago (June…

6 months ago

IDMC Provides Positive Recommendation for Bio-Thera Solution’s BAT4406F (ADCC-Enhanced Anti-CD20 mAb) in Neuromyelitis Optica Spectrum Disorder Based on Interim Analysis of Pivotal Phase II/III Trial

GUANGZHOU, China, July 2, 2025 /PRNewswire/ -- Bio-Thera Solutions, Inc. (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative…

6 months ago

Make Summer as Safe as It is Fun

MISSION, Kan., June 30, 2025 /PRNewswire/ -- (Family Features) With school out for summer, children will be away from teachers…

7 months ago

Dearborn Group and Symetra Reach Agreement on Acquisition of Dearborn Group’s Life & Disability Business

Dearborn Group shifts focus to core health offerings as Symetra adds scale to growing Workforce Benefits business Symetra to become…

7 months ago

Baylor Genetics Applauds New Guidance from American Academy of Pediatrics for Genome and Exome Sequencing to be used as First-Tier Tests for Children with Certain Developmental Delays

Guidance also outlines metabolic evaluation – like Baylor Genetics’ unique Global MAPS® untargeted metabolite screen – as second-tier testHOUSTON, June…

7 months ago

Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in…

7 months ago